# A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Source: https://onco.cc/trials/nct04711252/  
OnCo record `nct04711252` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Camizestrant and Palbociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease is a phase 3 interventional study registered as NCT04711252 by AstraZeneca, with 1370 participants enrolled, started 2021-01-28 and due to reach its primary completion in 2026-08-24. Interventions recorded: AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib and Luteinizing hormone-releasing hormone (LHRH) agonist.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04711252
- Phase: 3
- Setting: SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- Sponsor: AstraZeneca
- Enrolled: 1370

## Sources

- ClinicalTrials.gov NCT04711252: https://clinicaltrials.gov/study/NCT04711252

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Camizestrant](https://onco.cc/drugs/camizestrant/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04711252.json